Illumina, Inc.

Valuation Analysis

About the Company

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commerci

Illumina, Inc. Stock at a Glance

Illumina, Inc. (ILMN) is currently trading at $160.97 with a market capitalization of $24.4B. The trailing P/E ratio stands at 29.21x, with a forward P/E of 27.17x. The 52-week range spans from $86.03 to $177.22; the current price is 9.2% below the yearly high. Year-over-year revenue growth stands at +4.8%. The net profit margin stands at 19.42%.

💰 Dividend

Illumina, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

18 analysts rate Illumina, Inc. (ILMN) on consensus: Buy. The average price target is $147.17, implying -8.58% from the current price. Analyst price targets range from $95.00 to $185.00.

Illumina, Inc.: The Investment Case in Detail

Illumina, Inc. (ILMN) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 68.29%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 33.82% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 19.42%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Revenue growth has slowed to just 4.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (8.34%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Illumina, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.